Interactions Between Host And The Gut Microbiome In The Pathogenesis Of Ankylosing Spondylitis And Crohn's Disease
Funder
National Health and Medical Research Council
Funding Amount
$572,227.00
Summary
Ankylosing spondylitis (AS) and Crohn's disease (CD) are common immune-mediated diseases affecting primarily the joints of the spine and the gut respectively. Genes play a major role in determining the risk of each disease, and it is likely that those genes cause the disease by interaction with some environmental factor, most likely bacteria residing in the gut. This study aims to test that hypothesis by profiling the bacteria in the gut of patients with the diseases and healthy subjects.
Bacterial Inhibition Of Cell Signalling And Apoptosis During Gastrintestinal Infection
Funder
National Health and Medical Research Council
Funding Amount
$542,011.00
Summary
E. coli are a major cause of severe diarrhoeal disease. In order to establish infection, E. coli inhibits a host response where cells with bacteria stuck to them are ‘killed off’ and excreted as waste. This recent discovery illuminated an unknown role for cell death in the immune response during bacterial gastroenteritis. This project will study this phenomenon further to better understand the host immune response to infection and also other gut diseases such as inflammatory bowel disease.
A Novel Therapeutic Target For Preventing Helicobacter Pylori-associated Diseases
Funder
National Health and Medical Research Council
Funding Amount
$750,336.00
Summary
Gastric cancer mainly results from chronic inflammation (gastritis) caused by the stomach-dwelling bacterium, Helicobacter pylori. We have identified a potassium channel which our data suggest could be a new therapeutic target for protecting against gastric cancer caused by H. pylori infection. This project will test the role of this channel in H. pylori gastritis and see whether drugs that target this channel can protect mice against H. pylori-associated disease.
Impact Of Pneumococcal Vaccination And Environmental Factors On Pneumococcal Carriage And Disease.
Funder
National Health and Medical Research Council
Funding Amount
$455,872.00
Summary
Pneumonia is the leading killer of children <5y of age worldwide, and the pneumococcal bacterium is a common cause. Pneumococci are carried in the noses of healthy children. In this project we will determine 1) whether carriage can be used to monitor the impact of vaccination in resource-poor settings, 2) the effect of new vaccines on ear disease and transmission using infant mouse models and 3) if exposure to smoke effects the ability of pneumococci to cause disease and altered gene expressi ....Pneumonia is the leading killer of children <5y of age worldwide, and the pneumococcal bacterium is a common cause. Pneumococci are carried in the noses of healthy children. In this project we will determine 1) whether carriage can be used to monitor the impact of vaccination in resource-poor settings, 2) the effect of new vaccines on ear disease and transmission using infant mouse models and 3) if exposure to smoke effects the ability of pneumococci to cause disease and altered gene expression.Read moreRead less
A Serotype-independent, Broad Spectrum Pneumococcal Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$955,585.00
Summary
Streptococcus pneumoniae (the pneumococcus) is the world’s most formidable bacterial pathogen, causing 1-2 million deaths each year. Existing vaccines provide protection against only a limited proportion of strains and their widespread use is increasing the prevalence of strains against which the vaccines provide no protection. This project aims to translate a novel broadly protective pneumococcal vaccine into the commercial development pipeline.
Understanding The Role Of The Two Major Bacterial Pathogens In The Upper And Lower Airways Of Indigenous Children With Chronic Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$743,282.00
Summary
Lung infections are a major disease burden worldwide. Indigenous Australians are affected more; adults with severe lung disease can die in their 30s and 40s. These diseases start early, yet no in-depth studies of bacteria causing lung infections in children have been done. Our expert team proposes to use existing lung fluids from nearly 500 children with chronic lung disease (58% Indigenous), and state-of-the-art laboratory methods, to inform the design of vaccines to prevent lung disease.
Understanding Respiratory Infections To Improve Vaccines
Funder
National Health and Medical Research Council
Funding Amount
$268,497.00
Summary
Indigenous children have the highest rates of ear disease (OM) and associated hearing loss in the world. Papua New Guinea has the highest child mortality rates in the Western Pacific Region with 23% of deaths from pneumonia. OM and pneumonia vaccines can be improved through broadening their coverage of disease-causing pathogens. This study will identify the pathogens that currently cause OM in Indigenous children and pneumonia in PNG, and will measure the immune responses to these pathogens, in ....Indigenous children have the highest rates of ear disease (OM) and associated hearing loss in the world. Papua New Guinea has the highest child mortality rates in the Western Pacific Region with 23% of deaths from pneumonia. OM and pneumonia vaccines can be improved through broadening their coverage of disease-causing pathogens. This study will identify the pathogens that currently cause OM in Indigenous children and pneumonia in PNG, and will measure the immune responses to these pathogens, in order to develop improved vaccines.Read moreRead less
Pathogenesis, Treatment And Prevention Of Bacterial Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$852,458.00
Summary
Bacterial infectious diseases remain a serious threat to human health, accounting for over 10 million deaths each year. My research program aims to better understand the dynamic interactions between major disease-causing bacteria and their human hosts, and to directly apply this new knowledge to the development of improved vaccines and novel treatment strategies. These are urgently needed to combat bacterial infectious diseases in the 21st century.